Updated on 2025/05/01

写真a

 
HASHIZUME Atsushi
 
Organization
Nagoya University Hospital Professor
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Professor

Degree 1

  1. 医学博士 ( 2012.3   名古屋大学 ) 

Research Interests 6

  1. Clinical trials

  2. New drug development

  3. clinical research, neurology, drug evaluation

  4. Neurology

  5. Neurodegenerative diseases

  6. Clinical research education

Research Areas 2

  1. Life Science / Neurology  / Neurodegenerative diseases

  2. Life Science / Neurology

Current Research Project and SDGs 1

  1. Clinical research, Neurology

Research History 9

  1. Nagoya University   Clinical Research Education   Lecturer

    2021.7

  2. Nagoya University hospital   Lecturer   Lecturer of hospital

    2020.10 - 2021.6

      More details

    Country:Japan

  3. Nagoya University hospital   Neurology   Assistant professor of hospital

    2019.4 - 2020.9

      More details

    Country:Japan

  4. Nagoya University Graduate school of medicine   Department of Neurology   Designated assistant professor

    2018.9 - 2019.3

      More details

    Country:Japan

  5. Nagoya University hospital   Neurology   Clinical fellow

    2014.4 - 2018.8

      More details

    Country:Japan

▼display all

Education 3

  1. Nagoya University   Graduate School of Medicine

    2008.4 - 2012.3

  2. Nagoya University   school of medicine   department of medicine

    - 2002.3

      More details

    Country: Japan

  3. The University of Tokyo   school of medicine   department of health science

    - 1996.3

      More details

    Country: Japan

Professional Memberships 5

  1. The Japanese Society of. Clinical Pharmacology and Therapeutics   councilar

  2. Japanese society of neurology   academic member

  3. The Japanese society of internal medicine   academic member

  4. Japanese society of neurological therapeutics

  5. The Japan Stroke Society   academic member

Committee Memberships 7

  1. Japan Society of Neurology   Ethics  

    2023.4   

      More details

    Committee type:Academic society

  2. Pharmaceuticals and Medical divice Agency   医療上の必要性の高い未承認薬・適応外薬検討会議 循環器分野の専門作業班 構成員  

    2022.4   

      More details

    Committee type:Other

  3. Pharmaceutical and Medical Device Agency   Expert Advisor  

    2014.4   

  4. 日本神経治療学会   創薬推進委員  

       

  5. 日本神経学会   倫理・審査委員会  

       

▼display all

Awards 2

  1. 2019年 日本神経治療学会 治療学術賞

    2019.11   日本神経治療学会  

  2. 第56回日本神経学会学術大会 学術大会最優秀賞

    2015.5   日本神経学会  

 

Papers 172

  1. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA). Invited Reviewed

    Hashizume A, Fischbeck KH, Pennuto M, Fratta P, Katsuno M.

    J Neurol Neurosurg Psychiatry.   Vol. 91 ( 10 ) page: 123 - 130   2020.10

     More details

    Authorship:Lead author  

  2. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. Reviewed

    Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, Kishimoto Y, Moriyoshi H, Hirakawa A, Katsuno M.

    J Neurol.   Vol. 266 ( 12 ) page: 2952 - 2961   2019.12

     More details

    Authorship:Corresponding author   Language:English  

  3. Diffuse but Non-homogeneous Brain Atrophy: Identification of Specific Brain Regions and Their Correlation with Clinical Severity in Rett Syndrome Reviewed Open Access

    Narita H., Natsume J., Suzuki T., Shiohama T., Kawaguchi M., Okazaki M., Hashizume A., Naganawa S., Ito Y., Yamamoto H., Nakata T., Kidokoro H., Takahashi Y., Takahashi S., Tsujimura K.

    Brain and Development   Vol. 47 ( 3 ) page: 104348   2025.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Brain and Development  

    Background: Rett syndrome is a genetic neurodevelopmental disorder that predominantly affects girls. While microcephaly is a common feature, there is limited information on the detailed structural changes in the brain. This study aimed to identify regional brain volume abnormalities and explore the correlation between brain volume and clinical characteristics. Methods: We compared the regional brain volumes of 20 female children with Rett syndrome to those of 25 healthy female children. Additionally, we assessed the correlation between regional brain volume, Clinical Severity Scores, and epilepsy status. Results: Significantly smaller volumes were observed in all brain regions, including the cerebral cortex, cerebral white matter, subcortical gray matter, cerebellum, and brainstem. Within the cortical regions, volume reduction was prominent in the left precentral, right lateral occipital, left precuneus, left inferior parietal, and right medial orbitofrontal cortices. After correcting for intracranial volumes, volume reduction was more prominent in the cerebral cortices than in the cerebral white matter. Small volumes were consistently observed, regardless of age. Negative correlations were observed between the volumes of multiple regions and the Clinical Severity Scores. There were no correlations among regional brain volume, seizure control, or duration of epilepsy. Conclusion: The mechanism underlying the cortical-dominant volume reduction remains unclear; however, it may be caused by altered synapse development associated with methyl-CpG-binding protein 2 gene abnormalities. Characteristic impairments in visual recognition and deterioration of motor function in Rett syndrome may be associated with significant volume reduction in specific cortical regions, such as the lateral occipital cortex, precuneus, and precentral gyrus.

    DOI: 10.1016/j.braindev.2025.104348

    Open Access

    Scopus

    PubMed

  4. Re-evaluation of blood culture contamination rates: Discordance between clinical and laboratory assessment Reviewed

    Hamada, H; Morioka, H; Okazaki, M; Hashizume, A; Kanda, K; Oka, K; Iguchi, M; Yagi, T

    JOURNAL OF INFECTION AND CHEMOTHERAPY   Vol. 31 ( 4 ) page: 102628   2025.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Infection and Chemotherapy  

    DOI: 10.1016/j.jiac.2025.102628

    Web of Science

    Scopus

    PubMed

  5. Self-Organized Prediction-Classification-Superposition of Longitudinal Cognitive Decline in Alzheimer's Disease: An Application to Novel Clinical Research Methodology Reviewed

    Sato H., Hanazawa R., Suzuki K., Hashizume A., Hirakawa A.

    IEEE Journal of Biomedical and Health Informatics     2025

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:IEEE Journal of Biomedical and Health Informatics  

    Progressive cognitive decline spanning across decades is characteristic of Alzheimer's disease (AD). Various predictive models have been designed to realize its early onset and study the long-term trajectories of cognitive test scores across populations of interest. Research efforts have been geared towards superimposing patients' cognitive test scores with the long-term trajectory denoting gradual cognitive decline, while considering the heterogeneity of AD. Multiple trajectories representing cognitive assessment for the long-term have been developed based on various parameters, highlighting the importance of classifying several groups based on disease progression patterns. In this study, a novel method capable of self-organized prediction, classification, and the overlay of long-term cognitive trajectories based on short-term individual data was developed, based on statistical and differential equation modeling. Here, "self-organized"denotes a data-driven mechanism by which the prediction model adaptively configures its structure and parameters to classify individuals and estimate long-term trajectories. We validated the predictive accuracy of the proposed method on two cohorts: the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Japanese ADNI. We also presented two practical illustrations of the simultaneous evaluation of risk factor associated with both the onset and the longitudinal progression of AD, and an innovative randomized controlled trial design for AD that standardizes the heterogeneity of patients enrolled in a clinical trial. These resources would improve the power of statistical hypothesis testing and help evaluate the therapeutic effect. The application of predicting the trajectory of longitudinal disease progression goes beyond AD, and is especially relevant for progressive and neurodegenerative disorders.

    DOI: 10.1109/JBHI.2025.3546020

    Scopus

▼display all

Books 1

  1. 【神経疾患を克服する-わが国の戦略(1)】研究手法の最新の話題 臨床研究・疫学研究

    橋詰 淳, 倉沢 史門, 勝野 雅央( Role: Joint author)

    中外医学社  2021.9 

     More details

    Responsible for pages:5   Language:Japanese Book type:Scholarly book

MISC 66

  1. 日本神経学会・日本神経治療学会合同シンポジウム:神経疾患領域の医薬品開発を最速化するために 神経疾患領域の医薬品開発における現状の課題と展望

    橋詰 淳, 勝野 雅央

    臨床神経学   Vol. 63 ( Suppl. ) page: S8 - S8   2023.9

     More details

    Language:Japanese   Publisher:(一社)日本神経学会  

  2. 球脊髄性筋萎縮症に対する自記式評価指標SBMAPROの開発

    橋詰 淳, 山田 晋一郎, 伊藤 大輔, 岸本 祥之, 小森 祥太, 森田 光哉, 山本 知孝, 勝野 雅央

    臨床神経学   Vol. 63 ( Suppl. ) page: S297 - S297   2023.9

     More details

    Language:Japanese   Publisher:(一社)日本神経学会  

  3. 筋萎縮性側索硬化症における発症前症状の検討

    小森 祥太, 橋詰 淳, 山田 晋一郎, 伊藤 大輔, 岸本 祥之, 勝野 雅央

    臨床神経学   Vol. 63 ( Suppl. ) page: S247 - S247   2023.9

     More details

    Language:Japanese   Publisher:(一社)日本神経学会  

  4. 球脊髄性筋萎縮症患者における遺伝リテラシーの調査

    山田 晋一郎, 橋詰 淳, 伊藤 大輔, 岸本 祥之, 小森 祥太, 勝野 雅央

    臨床神経学   Vol. 63 ( Suppl. ) page: S297 - S297   2023.9

     More details

    Language:Japanese   Publisher:(一社)日本神経学会  

  5. 【脳神経内科における予防医療】神経変性疾患と予防医療

    勝野 雅央, 橋詰 淳

    神経治療学   Vol. 40 ( 2 ) page: 74 - 78   2023.3

▼display all

Presentations 4

  1. 脳神経内科医が知っておくべき臨床薬理学の視点 ~ 医薬品開発・レギュラトリーサイエンス ~ Invited

    橋詰 淳

    第65回日本神経学会学術大会  2024.5.30  日本神経学会

     More details

    Event date: 2024.5

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  2. 運動ニューロン疾患の新規治療とエビデンス 球脊髄性筋萎縮症に対するリュープロレリン酢酸塩治療とリアルワールドデータ Invited

    橋詰 淳

    第39回日本神経治療学会学術集会  2021.10.29  日本神経治療学会

     More details

    Event date: 2021.10

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:三重   Country:Japan  

  3. 研究者対象セミナー「実例から学ぶ観察研究デザインの基礎」 Invited

    橋詰 淳

    日本臨床試験学会 教育セミナー  2024.8.31  日本臨床試験学会

     More details

    Event date: 2024.8

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:東京   Country:Japan  

  4. 脳神経内科医も知っておくべき 臨床研究に関連する各種規制 イントロダクション Invited

    橋詰 淳

    第63回日本神経学会学術大会  2022.5.20  日本神経学会

     More details

    Event date: 2022.5

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

KAKENHI (Grants-in-Aid for Scientific Research) 14

  1. 球脊髄性筋萎縮症の適正治療に関するエビデンス構築のための臨床研究

    Grant number:18950395  2018.4 - 2021.3

    国立研究開発法人日本医療研究開発機構  日本医療研究開発機構研究費 

    勝野雅央 橋詰淳 土方靖浩 山本知孝 森田光哉

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

    Grant amount:\43200000 ( Direct Cost: \33230771 、 Indirect Cost:\9969229 )

  2. 球脊髄性筋萎縮症に対するリュープリロレリン酢酸塩長期投与時の有効性評価

    Grant number:18973939  2018.4 - 2021.3

    文部科学省  科学研究費助成事業  基盤研究(C)

    橋詰淳 勝野雅央

      More details

    Grant type:Competitive

    Grant amount:\6500000 ( Direct Cost: \5000000 、 Indirect Cost:\1500000 )

  3. 球脊髄性筋萎縮症の神経筋システム変性を標的とした革新的治療法開発

    Grant number:17929518  2017.4 - 2019.3

    国立研究開発法人日本医療研究開発機構  日本医療研究開発機構研究費 

    勝野雅央 佐橋健太郎 橋詰淳 近藤直英

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

    Grant amount:\87690000 ( Direct Cost: \67454000 、 Indirect Cost:\20236000 )

  4. レジストリ構築による球脊髄性筋萎縮症の早期バイオマーカー開発

    Grant number:15565388  2015.4 - 2018.3

    文部科学省  科学研究費助成事業 

    橋詰淳 勝野雅央 祖父江元

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\6500000 ( Direct Cost: \5000000 )

  5. 臨床研究のDXに即応した球脊髄性筋萎縮症レジストリの構築と病態マーカーの同定

    Grant number:24K10658  2024.4 - 2027.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    橋詰 淳, 山田 晋一郎, 勝野 雅央, 山田 晋一郎, 勝野 雅央

      More details

    Authorship:Principal investigator 

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    本研究課題では、SBMA臨床研究の電磁化(Digital transformation、以下、DX化)を推進し、遠隔地の患者も組み入れ可能なレジストリを構築する。さらに、SBMAの治療反応性の判断や早期患者の臨床評価に有用、かつ、DX技術に基づき遠隔評価可能なバイオマーカー(以下、DX化バイオマーカー)を同定することで、DX化に即応した新しい疾患レジストリへと発展させる。

▼display all

 

Teaching Experience (On-campus) 26

  1. 臨床研究教育学臨床実習

    2024

  2. 選択科目 臨床試験

    2024

  3. 大学院ベーシックトレーニング

    2024

  4. 臨床研究教育学臨床実習

    2023

  5. 選択科目 臨床試験

    2023

▼display all